Search

Your search keyword '"Larman M"' showing total 113 results
Start Over Author "Larman M"
113 results on '"Larman M"'

4. P-141 Independent external pre-clinical validation of iDAScore v1.0 in 1232 PGT-A cycles with 3604 biopsied blastocysts and 808 euploid transfers.

Author

Casciani, V, primary, Cimadomo, D, additional, Chiappetta, V, additional, Innocenti, F, additional, Saturno, G, additional, Albricci, L, additional, Maggiulli, R, additional, Coticchio, G, additional, Ahlström, A, additional, Berntsen, J, additional, Larman, M, additional, Borini, A, additional, Vaiarelli, A, additional, Ubaldi, F M, additional, and Rienzi, L, additional

Published
2023
Full Text
View/download PDF

5. P-189 Association between iDAScore v1.0, senior embryologists’ grading and euploidy in 546 blastocysts obtained during 189 PGT-A cycles

Author

Casciani, V, primary, Cimadomo, D, additional, Trio, S, additional, Chiappetta, V, additional, Innocenti, F, additional, Iussig, B, additional, Alviggi, E, additional, Canosa, S, additional, Barnocchi, N, additional, Maggiulli, R, additional, Berntsen, J, additional, Kragh, M.F, additional, Larman, M, additional, Ubaldi, F.M, additional, and Rienzi, L, additional

Published
2022
Full Text
View/download PDF

6. Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With ST-Segment Elevation Myocardial Infarction and Left Ventricular Dysfunction

Author

Fernández-Avilés F, Sanz-Ruiz R, Bogaert J, Casado Plasencia A, Gilaberte I, Belmans A, Fernández-Santos ME, Charron D, Mulet M, Yotti R, Palacios I, Luque M, Sádaba R, San Román JA, Larman M, Sánchez PL, Sanchís J, Jiménez MF, Claus P, Al-Daccak R, Lombardo E, Abad JL, DelaRosa O, Corcóstegui L, Bermejo J, and Janssens S

Subjects
Male, Ventricular Dysfunction, Left, Myocardial Infarction, Humans, Infusions, Intra-Arterial, Transplantation, Homologous, Female, Middle Aged, Myoblasts, Cardiac, Aged, Stem Cell Transplantation
Abstract

Allogeneic cardiac stem cells (AlloCSC-01) have shown protective, immunoregulatory, and regenerative properties with a robust safety profile in large animal models of heart disease.To investigate the safety and feasibility of early administration of AlloCSC-01 in patients with ST-segment-elevation myocardial infarction.CAREMI (Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With STEMI and Left Ventricular Dysfunction) was a phase I/II multicenter, randomized, double-blind, placebo-controlled trial in patients with ST-segment-elevation myocardial infarction, left ventricular ejection fraction ≤45%, and infarct size ≥25% of left ventricular mass by cardiac magnetic resonance, who were randomized (2:1) to receive AlloCSC-01 or placebo through the intracoronary route at days 5 to 7. The primary end point was safety and included all-cause death and major adverse cardiac events at 30 days (all-cause death, reinfarction, hospitalization because of heart failure, sustained ventricular tachycardia, ventricular fibrillation, and stroke). Secondary safety end points included major adverse cardiac events at 6 and 12 months, adverse events, and immunologic surveillance. Secondary exploratory efficacy end points were changes in infarct size (percentage of left ventricular mass) and indices of ventricular remodeling by magnetic resonance at 12 months. Forty-nine patients were included (92% male, 55±11 years), 33 randomized to AlloCSC-01 and 16 to placebo. No deaths or major adverse cardiac events were reported at 12 months. One severe adverse events in each group was considered possibly related to study treatment (allergic dermatitis and rash). AlloCSC-01 elicited low levels of donor-specific antibodies in 2 patients. No immune-related adverse events were found, and no differences between groups were observed in magnetic resonance-based efficacy parameters at 12 months. The estimated treatment effect of AlloCSC-01 on the absolute change from baseline in infarct size was -2.3% (95% confidence interval, -6.5% to 1.9%).AlloCSC-01 can be safely administered in ST-segment-elevation myocardial infarction patients with left ventricular dysfunction early after revascularization. Low immunogenicity and absence of immune-mediated events will facilitate adequately powered studies to demonstrate their clinical efficacy in this setting.URL: http://www.clinicaltrials.gov . Unique identifier: NCT02439398.

Published
2018

7. Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

Author

De la Torre Hernández JM, Sadaba Sagredo M, Telleria Arrieta M, Gimeno de Carlos F, Sanchez Lacuesta E, Bullones Ramírez JA, Pineda Rocamora J, Martin Yuste V, Garcia Camarero T, Larman M, and Rumoroso JR

Subjects
Thrombolytic therapy, Anticoagulation, Angioplasty, Acute myocardial infarction
Abstract

Background: Thrombolysis is still used when primary angioplasty is delayed for a long time, but 25%-30% of patients require rescue angioplasty (RA). There are no established recommendations for antithrombotic management in RA. This registry analyzes regimens for antithrombotic management. Methods: A retrospective, multicenter, observational registry of consecutive patients treated with RA at 8 hospitals. All variables were collected and follow-up took place at 6 months. Results: The study included 417 patients. Antithrombotic therapy in RA was: no additional drugs 22.3%, unfractionated heparin (UFH) 36.6%, abciximab 15.5%, abciximab plus UFH 10.5%, bivalirudin 5.7%, enoxaparin 4.3%, and others 4.7%. Outcomes at 6 months were: mortality 9.1%, infarction 3.3%, definite or probable stent thrombosis 4.3%, revascularization 1.9%, and stroke 0.5%. Mortality was related to cardiogenic shock, age > 75 years, and anterior location. The stent thrombosis rate was highest with bivalirudin (12.5% at 6 months). The incidence of bleeding at admission was high (14.8%), but most cases were not severe (82% BARC

Published
2017

8. P752Acquired intracardiac shunts following transcatheter aortic valve replacement

Author

Amat Santos, I.J., primary, Rojas, P., additional, Nombela-Franco, L., additional, Lezaun, R., additional, Rodriguez-Olivares, R., additional, Gutierrez-Ibanes, E., additional, Munoz-Garcia, A.J., additional, Stella, P.R., additional, Hernandez-Antolin, R., additional, Serra, V., additional, Larman, M., additional, Vera, S., additional, Martin-Morquecho, I., additional, Gomez, I., additional, and San Roman, J.A., additional

Published
2017
Full Text
View/download PDF

9. P6348Main predictors of mortality in TAVR patients with previous mitral prosthesis

Author

Amat-Santos, I.J., primary, Cortes Villar, C., additional, Suarez De Lezo, J.L., additional, Munoz-Garcia, J.A., additional, Hernandez, J.M., additional, Nombela-Franco, L., additional, Jimenez-Quevedo, P., additional, Gutierrez, E., additional, De La Torre, J.M., additional, Larman, M., additional, Serra, V., additional, Garcia, B., additional, Moreno, R., additional, Carrasco-Moraleja, M., additional, and San Roman, J.A., additional

Published
2017
Full Text
View/download PDF

10. P5128Imaging evaluation of transcatheter aortic valve recipients harbouring previous mitral protheses

Author

Amat-Santos, I.J., primary, Cortes Villar, C., additional, Suarez De Lezo, J.A., additional, Munoz, J.A., additional, Castrodeza, J.A., additional, Nombela-Franco, L., additional, Jimenez-Quevedo, P., additional, Gutierrez, E., additional, De La Torre, J.M., additional, Larman, M., additional, Serra, V., additional, Martin-Morquecho, I.J., additional, Moreno, R.A.U.L., additional, Gomez, I., additional, and San Roman, J.A., additional

Published
2017
Full Text
View/download PDF

11. P6346Transcatheter aortic valve replacement in patients with previous mitral prostheses

Author

Cortes Villar, C., primary, Amat-Santos, I.J., additional, Suarez De Lezo, J., additional, Munoz-Garcia, J.A., additional, Hernandez, J.M., additional, Nombela-Franco, L., additional, Jimenez-Quevedo, P., additional, Gutierrez, E., additional, De La Torre, J.M., additional, Larman, M., additional, Serra, V., additional, Garcia, B., additional, Moreno, R., additional, Gomez, I.J., additional, and San Roman, J.A., additional

Published
2017
Full Text
View/download PDF

13. Meeting Report

Author

Larman M and Lucy J

Subjects
symbols.namesake, Chemistry, Vesicular-tubular cluster, Endoplasmic reticulum, symbols, STIM1, Cell Biology, Golgi apparatus, Molecular Biology, Secretory pathway, Structure and function, Cell biology
Published
1999
Full Text
View/download PDF

14. Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease

Author

Goikoetxea, M.J. (María J.), Beaumont, J. (Javier), Gonzalez, A. (Arantxa), Lopez-Salazar, M.B. (María Begoña), Querejeta, R. (Ramón), Larman, M. (Mariano), and Diez-Martinez, J. (Javier)

Subjects
Hypertension, cardiovascular system, Heart failure, cardiovascular diseases, Hypertrophy, Peroxisome proliferator-activated receptor alpha, Isoforms
Abstract

OBJECTIVE: To investigate whether cardiac expression of the nuclear peroxisome proliferator-activated receptor alpha (PPARalpha) is altered in patients with hypertensive heart disease (HHD). METHODS: We studied endomyocardial septal biopsies from 24 patients with essential hypertension divided into three groups: 6 without left ventricular hypertrophy (LVH) (HT group), 10 with LVH (LVH group), and 8 with LVH and heart failure (HF) (HF group). The expression of two PPARalpha isoforms (the native active and the truncated inhibitory) was analyzed by Western blot and reverse transcription polymerase chain reaction (RT-PCR), and two PPARalpha target genes were evaluated by RT-PCR. Histomorphological features were evaluated in a second myocardial sample from LVH and HF groups. RESULTS: Whereas the expression of native PPARalpha protein was lower (p

Published
2006

15. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis

Author

Querejeta, R. (Ramón), Lopez-Salazar, M.B. (María Begoña), Gonzalez, A. (Arantxa), Sanchez, E. (Eloy), Larman, M. (Mariano), Martinez-Ubago, J.L. (José L.), and Diez-Martinez, J. (Javier)

Subjects
Myocardium, Hypertension, Heart failure, Collagen, Peptides
Abstract

BACKGROUND: We investigated whether increased collagen type I synthesis and deposition contribute to enhancement of myocardial fibrosis and deterioration of cardiac function in patients with hypertensive heart disease (HHD). METHODS AND RESULTS: We studied 65 hypertensives with left ventricular hypertrophy subdivided into 2 groups: 34 patients without heart failure (HF) and 31 patients with HF. Transvenous endomyocardial biopsies of the interventricular septum were performed to quantify the amount of fibrotic tissue and the extent of collagen type I deposition. The carboxy-terminal propeptide of procollagen type I (PIP), an index of collagen type I synthesis, was measured by radioimmunoassay in serum samples from the coronary sinus and the antecubital vein. Compared with normotensives, the amount of collagen tissue, the extent of collagen type I deposition, and coronary and peripheral PIP were increased (P

Published
2004

16. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients

Author

Lopez-Salazar, M.B. (María Begoña), Querejeta, R. (Ramón), Varo-Cenarruzabeitia, M.N. (Miren Nerea), Gonzalez, A. (Arantxa), Larman, M. (Mariano), Martinez-Ubago, J.L. (José L.), and Diez-Martinez, J. (Javier)

Subjects
Myocardium, Hypertension, Collagen, Peptides, Remodeling
Abstract

BACKGROUND: We investigated whether serum concentration of carboxy-terminal propeptide of procollagen type I (PIP), a marker of collagen type I synthesis, can be used to assess the ability of antihypertensive treatment to regress myocardial fibrosis in hypertensive patients. METHODS AND RESULTS: The study was performed in 37 patients with essential hypertension and hypertensive heart disease. After randomization, 21 patients were assigned to losartan and 16 patients to amlodipine treatment. At baseline and after 12 months, right septal endomyocardial biopsies were performed to quantify collagen volume fraction (CVF) on picrosirius red-stained sections with an automated image-analysis system. Serum PIP was measured by specific radioimmunoassay. Nineteen patients in the losartan group and 11 in the amlodipine group finished the study. Time-course changes in blood pressure during treatment were similar in the 2 groups of patients. In losartan-treated patients, CVF decreased from 5.65+/-2.03% to 3.96+/-1.46% (P

Published
2001

17. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease

Author

Querejeta, R. (Ramón), Varo-Cenarruzabeitia, M.N. (Miren Nerea), Lopez-Salazar, M.B. (María Begoña), Larman, M. (Mariano), Artiñano, E. (E.), Etayo, J.C. (Juan Carlos), Martinez-Ubago, J.L. (José L.), Gutierrez-Stampa, M. (M.), Emparanza, J.I. (J. I.), Gil, M.J. (María José), Monreal, J.I. (José Ignacio), Pardo-Mindan, F.J. (Francisco Javier), and Diez-Martinez, J. (Javier)

Subjects
Myocardium, Hypertension, Collagen, Peptides, Remodeling
Abstract

BACKGROUND: This study was designed to investigate whether the serum concentration of the carboxy-terminal propeptide of procollagen type I (PIP), a marker of collagen type I synthesis, is related to myocardial fibrosis in hypertensive patients. METHODS AND RESULTS: The study was performed in 26 patients with essential hypertension in which ischemic cardiomyopathy was excluded after a complete medical workup. Right septal endomyocardial biopsies were performed in hypertensive patients to quantify collagen content. Collagen volume fraction (CVF) was determined on picrosirius red-stained sections with an automated image analysis system. The serum concentration of PIP was measured by specific radioimmunoassay. Compared with normotensives, both serum PIP and CVF were increased (P

Published
2000

19. Embryology

Author

Gandhi, G., primary, Allahbadia, G., additional, Kagalwala, S., additional, Allahbadia, A., additional, Ramesh, S., additional, Patel, K., additional, Hinduja, R., additional, Chipkar, V., additional, Madne, M., additional, Ramani, R., additional, Joo, J. K., additional, Jeung, J. E., additional, Go, K. R., additional, Lee, K. S., additional, Goto, H., additional, Hashimoto, S., additional, Amo, A., additional, Yamochi, T., additional, Iwata, H., additional, Morimoto, Y., additional, Koifman, M., additional, Lahav-Baratz, S., additional, Blais, E., additional, Megnazi-Wiener, Z., additional, Ishai, D., additional, Auslender, R., additional, Dirnfeld, M., additional, Zaletova, V., additional, Zakharova, E., additional, Krivokharchenko, I., additional, Zaletov, S., additional, Zhu, L., additional, Li, Y., additional, Zhang, H., additional, Ai, J., additional, Jin, L., additional, Zhang, X., additional, Rajan, N., additional, Kovacs, A., additional, Foley, C., additional, Flanagan, J., additional, O'Callaghan, J., additional, Waterstone, J., additional, Dineen, T., additional, Dahdouh, E. M., additional, St-Michel, P., additional, Granger, L., additional, Carranza-Mamane, B., additional, Faruqi, F., additional, Kattygnarath, T. V., additional, Gomes, F. L. A. F., additional, Christoforidis, N., additional, Ioakimidou, C., additional, Papas, C., additional, Moisidou, M., additional, Chatziparasidou, A., additional, Klaver, M., additional, Tilleman, K., additional, De Sutter, P., additional, Lammers, J., additional, Freour, T., additional, Splingart, C., additional, Barriere, P., additional, Ikeno, T., additional, Nakajyo, Y., additional, Sato, Y., additional, Hirata, K., additional, Kyoya, T., additional, Kyono, K., additional, Campos, F. B., additional, Meseguer, M., additional, Nogales, M., additional, Martinez, E., additional, Ariza, M., additional, Agudo, D., additional, Rodrigo, L., additional, Garcia-Velasco, J. A., additional, Lopes, A. S., additional, Frederickx, V., additional, Vankerkhoven, G., additional, Serneels, A., additional, Roziers, P., additional, Puttermans, P., additional, Campo, R., additional, Gordts, S., additional, Fragouli, E., additional, Alfarawati, S., additional, Spath, K., additional, Wells, D., additional, Liss, J., additional, Lukaszuk, K., additional, Glowacka, J., additional, Bruszczynska, A., additional, Gallego, S. C., additional, Lopez, L. O., additional, Vila, E. O., additional, Garcia, M. G., additional, Canas, C. L., additional, Segovia, A. G., additional, Ponce, A. G., additional, Calonge, R. N., additional, Peregrin, P. C., additional, Ito, K., additional, Nakaoka, Y., additional, Alcoba, D. D., additional, Valerio, E. G., additional, Conzatti, M., additional, Tornquist, J., additional, Kussler, A. P., additional, Pimentel, A. M., additional, Corleta, H. E., additional, Brum, I. S., additional, Boyer, P., additional, Montjean, D., additional, Tourame, P., additional, Gervoise-Boyer, M., additional, Cohen, J., additional, Lefevre, B., additional, Radio, C. I., additional, Wolf, J. P., additional, Ziyyat, A., additional, De Croo, I., additional, Tolpe, A., additional, Degheselle, S., additional, Van de Velde, A., additional, Van den Abbeel, E., additional, Gandhi, G., additional, Kuwayama, M., additional, Khatoon, A., additional, Alsule, S., additional, Inaba, M., additional, Ohgaki, A., additional, Ohtani, A., additional, Matsumoto, H., additional, Mizuno, S., additional, Mori, R., additional, Fukuda, A., additional, Umekawa, Y., additional, Yoshida, A., additional, Tanigiwa, S., additional, Seida, K., additional, Suzuki, H., additional, Tanaka, M., additional, Vahabi, Z., additional, Yazdi, P. E., additional, Dalman, A., additional, Ebrahimi, B., additional, Mostafaei, F., additional, Niknam, M. R., additional, Watanabe, S., additional, Kamihata, M., additional, Tanaka, T., additional, Matsunaga, R., additional, Yamanaka, N., additional, Kani, C., additional, Ishikawa, T., additional, Wada, T., additional, Morita, H., additional, Miyamura, H., additional, Nishio, E., additional, Ito, M., additional, Kuwahata, A., additional, Ochi, M., additional, Horiuchi, T., additional, Dal Canto, M., additional, Guglielmo, M. C., additional, Fadini, R., additional, Renzini, M. M., additional, Albertini, D. F., additional, Novara, P., additional, Lain, M., additional, Brambillasca, F., additional, Turchi, D., additional, Sottocornola, M., additional, Coticchio, G., additional, Kato, M., additional, Fukunaga, N., additional, Nagai, R., additional, Kitasaka, H., additional, Yoshimura, T., additional, Tamura, F., additional, Hasegawa, N., additional, Nakayama, K., additional, Takeuchi, M., additional, Ohno, H., additional, Aoyagi, N., additional, Kojima, E., additional, Itoi, F., additional, Hashiba, Y., additional, Asada, Y., additional, Kikuchi, H., additional, Iwasa, Y., additional, Kamono, T., additional, Suzuki, A., additional, Yamada, K., additional, Kanno, H., additional, Sasaki, K., additional, Murakawa, H., additional, Matsubara, M., additional, Yoshida, H., additional, Valdespin, C., additional, Elhelaly, M., additional, Chen, P., additional, Pangestu, M., additional, Catt, S., additional, Hojnik, N., additional, Kovacic, B., additional, Roglic, P., additional, Taborin, M., additional, Zafosnik, M., additional, Knez, J., additional, Vlaisavljevic, V., additional, Mori, C., additional, Yabuuchi, A., additional, Ezoe, K., additional, Takayama, Y., additional, Aono, F., additional, Kato, K., additional, Radwan, P., additional, Krasinski, R., additional, Chorobik, K., additional, Radwan, M., additional, Stoppa, M., additional, Maggiulli, R., additional, Capalbo, A., additional, Ievoli, E., additional, Dovere, L., additional, Scarica, C., additional, Albricci, L., additional, Romano, S., additional, Sanges, F., additional, Barnocchi, N., additional, Papini, L., additional, Vivarelli, A., additional, Ubaldi, F. M., additional, Rienzi, L., additional, Bono, S., additional, Spizzichino, L., additional, Rubio, C., additional, Fiorentino, F., additional, Ferris, J., additional, Favetta, L. A., additional, MacLusky, N., additional, King, W. A., additional, Madani, T., additional, Jahangiri, N., additional, Aflatoonian, R., additional, Cater, E., additional, Hulme, D., additional, Berrisford, K., additional, Jenner, L., additional, Campbell, A., additional, Fishel, S., additional, Zhang, X. Y., additional, Yilmaz, A., additional, Hananel, H., additional, Ao, A., additional, Vutyavanich, T., additional, Piromlertamorn, W., additional, Saenganan, U., additional, Samchimchom, S., additional, Wirleitner, B., additional, Lejeune, B., additional, Zech, N. H., additional, Vanderzwalmen, P., additional, Albani, E., additional, Parini, V., additional, Smeraldi, A., additional, Menduni, F., additional, Antonacci, R., additional, Marras, A., additional, Levi, S., additional, Morreale, G., additional, Pisano, B., additional, Di Biase, A., additional, Di Rosa, A., additional, Setti, P. E. L., additional, Puard, V., additional, Cadoret, V., additional, Tranchant, T., additional, Gauthier, C., additional, Reiter, E., additional, Guerif, F., additional, Royere, D., additional, Yoon, S. Y., additional, Eum, J. H., additional, Park, E. A., additional, Kim, T. Y., additional, Yoon, T. K., additional, Lee, D. R., additional, Lee, W. S., additional, Cabal, A. C., additional, Vallejo, B., additional, Campos, P., additional, Sanchez, E., additional, Serrano, J., additional, Remohi, J., additional, Nagornyy, V., additional, Mazur, P., additional, Mykytenko, D., additional, Semeniuk, L., additional, Zukin, V., additional, Guilherme, P., additional, Madaschi, C., additional, Bonetti, T. C. S., additional, Fassolas, G., additional, Izzo, C. R., additional, Santos, M. J. D. L., additional, Beltran, D., additional, Garcia-Laez, V., additional, Escriba, M. J., additional, Grau, N., additional, Escrich, L., additional, Albert, C., additional, Zuzuarregui, J. L., additional, Pellicer, A., additional, LU, Y., additional, Nikiforaki, D., additional, Meerschaut, F. V., additional, Neupane, J., additional, De Vos, W. H., additional, Lierman, S., additional, Deroo, T., additional, Heindryckx, B., additional, Li, J., additional, Chen, X. Y., additional, Lin, G., additional, Huang, G. N., additional, Sun, Z. Y., additional, Zhong, Y., additional, Zhang, B., additional, Li, T., additional, Zhang, S. P., additional, Ye, H., additional, Han, S. B., additional, Liu, S. Y., additional, Zhou, J., additional, Lu, G. X., additional, Zhuang, G. L., additional, Muela, L., additional, Roldan, M., additional, Gadea, B., additional, Martinez, M., additional, Perez, I., additional, Munoz, M., additional, Castello, C., additional, Asensio, M., additional, Fernandez, P., additional, Farreras, A., additional, Rovira, S., additional, Capdevila, J. M., additional, Velilla, E., additional, Lopez-Teijon, M., additional, Kovacs, P., additional, Matyas, S. Z., additional, Forgacs, V., additional, Reichart, A., additional, Rarosi, F., additional, Bernard, A., additional, Torok, A., additional, Kaali, S. G., additional, Sajgo, A., additional, Pribenszky, C. S., additional, Sozen, B., additional, Ozturk, S., additional, Yaba-Ucar, A., additional, Demir, N., additional, Gelo, N., additional, Stanic, P., additional, Hlavati, V., additional, ogoric, S., additional, Pavicic-Baldani, D., additional, prem-Goldtajn, M., additional, Radakovic, B., additional, Kasum, M., additional, Strelec, M., additional, Canic, T., additional, imunic, V., additional, Vrcic, H., additional, Ajina, M., additional, Negra, D., additional, Ben-Ali, H., additional, Jallad, S., additional, Zidi, I., additional, Meddeb, S., additional, Bibi, M., additional, Khairi, H., additional, Saad, A., additional, Gamiz, P., additional, Viloria, T., additional, Lima, E. T., additional, Fernandez, M. P., additional, Prieto, J. A. A., additional, Varela, M. O., additional, Kassa, D., additional, Munoz, E. M., additional, Kani, K., additional, Nor-Ashikin, M. N. K., additional, Norhazlin, J. M. Y., additional, Norita, S., additional, Wan-Hafizah, W. J., additional, Mohd-Fazirul, M., additional, Razif, D., additional, Hoh, B. P., additional, Dale, S., additional, Woodhead, G., additional, Andronikou, S., additional, Francis, G., additional, Tailor, S., additional, Vourliotis, M., additional, Almeida, P. A., additional, Krivega, M., additional, Van de Velde, H., additional, Lee, R. K., additional, Hwu, Y. M., additional, Lu, C. H., additional, Li, S. H., additional, Vaiarelli, A., additional, Desgro, M., additional, Baggiani, A., additional, Zannoni, E., additional, Kermavner, L. B., additional, Klun, I. V., additional, Pinter, B., additional, Vrtacnik-Bokal, E., additional, De Paepe, C., additional, Cauffman, G., additional, Verheyen, G., additional, Stoop, D., additional, Liebaers, I., additional, Stecher, A., additional, Zintz, M., additional, Neyer, A., additional, Bach, M., additional, Baramsai, B., additional, Schwerda, D., additional, Wiener-Megnazi, Z., additional, Fridman, M., additional, Blais, I., additional, Akerud, H., additional, Lindgren, K., additional, Karehed, K., additional, Wanggren, K., additional, Hreinsson, J., additional, Freijomil, B., additional, Weiss, A., additional, Neril, R., additional, Geslevich, J., additional, Beck-Fruchter, R., additional, Lavee, M., additional, Golan, J., additional, Ermoshkin, A., additional, Shalev, E., additional, Shi, W., additional, Zhang, S., additional, Zhao, W., additional, Xue, X. I. A., additional, Wang, M. I. N., additional, Bai, H., additional, Shi, J., additional, Smith, H. L., additional, Shaw, L., additional, Kimber, S., additional, Brison, D., additional, Boumela, I., additional, Assou, S., additional, Haouzi, D., additional, Ahmed, O. A., additional, Dechaud, H., additional, Hamamah, S., additional, Dasiman, R., additional, Nor-Shahida, A. R., additional, Salina, O., additional, Gabriele, R. A. F., additional, Ben-Yosef, D., additional, Shwartz, T., additional, Cohen, T., additional, Carmon, A., additional, Raz, N. M., additional, Malcov, M., additional, Frumkin, T., additional, Almog, B., additional, Vagman, I., additional, Kapustiansky, R., additional, Reches, A., additional, Azem, F., additional, Amit, A., additional, Cetinkaya, M., additional, Pirkevi, C., additional, Yelke, H., additional, Kumtepe, Y., additional, Atayurt, Z., additional, Kahraman, S., additional, Risco, R., additional, Hebles, M., additional, Saa, A. M., additional, Vilches-Ferron, M. A., additional, Sanchez-Martin, P., additional, Lucena, E., additional, Lucena, M., additional, Heras, M. D. L., additional, Agirregoikoa, J. A., additional, Barrenetxea, G., additional, De Pablo, J. L., additional, Lehner, A., additional, Pribenszky, C., additional, Murber, A., additional, Rigo, J., additional, Urbancsek, J., additional, Fancsovits, P., additional, Bano, D. G., additional, Sanchez-Leon, A., additional, Marcos, J., additional, Molla, M., additional, Amorocho, B., additional, Nicolas, M., additional, Fernandez, L., additional, Landeras, J., additional, Adeniyi, O. A., additional, Ehbish, S. M., additional, Brison, D. R., additional, Egashira, A., additional, Murakami, M., additional, Nagafuchi, E., additional, Tanaka, K., additional, Tomohara, A., additional, Mine, C., additional, Otsubo, H., additional, Nakashima, A., additional, Otsuka, M., additional, Yoshioka, N., additional, Kuramoto, T., additional, Choi, D., additional, Yang, H., additional, Park, J. H., additional, Jung, J. H., additional, Hwang, H. G., additional, Lee, J. H., additional, Lee, J. E., additional, Kang, A. S., additional, Yoo, J. H., additional, Kwon, H. C., additional, Lee, S. J., additional, Bang, S., additional, Shin, H., additional, Lim, H. J., additional, Min, S. H., additional, Yeon, J. Y., additional, Koo, D. B., additional, Higo, S., additional, Ruvalcaba, L., additional, Kobayashi, M., additional, Takeuchi, T., additional, Miwa, A., additional, Nagai, Y., additional, Momma, Y., additional, Takahashi, K., additional, Chuko, M., additional, Nagai, A., additional, Otsuki, J., additional, Kim, S. G., additional, Kim, Y. Y., additional, Kim, H. J., additional, Park, I. H., additional, Sun, H. G., additional, Lee, K. H., additional, Song, H. J., additional, Costa-Borges, N., additional, Belles, M., additional, Herreros, J., additional, Teruel, J., additional, Ballesteros, A., additional, Calderon, G., additional, Vossaert, L., additional, Qian, C., additional, Lu, Y., additional, Parys, J. B., additional, Deforce, D., additional, Leybaert, L., additional, Surlan, L., additional, Otasevic, V., additional, Velickovic, K., additional, Golic, I., additional, Vucetic, M., additional, Stankovic, V., additional, Stojnic, J., additional, Radunovic, N., additional, Tulic, I., additional, Korac, B., additional, Korac, A., additional, Elias, R., additional, Neri, Q. V., additional, Fields, T., additional, Schlegel, P. N., additional, Rosenwaks, Z., additional, Palermo, G. D., additional, Gilson, A., additional, Piront, N., additional, Heens, B., additional, Vastersaegher, C., additional, Vansteenbrugge, A., additional, Pauwels, P. C. P., additional, Abdel-Raheem, M. F., additional, Abdel-Rahman, M. Y., additional, Abdel-Gaffar, H. M., additional, Sabry, M., additional, Kasem, H., additional, Rasheed, S. M., additional, Amin, M., additional, Abdelmonem, A., additional, Ait-Allah, A. S., additional, VerMilyea, M., additional, Anthony, J., additional, Bucci, J., additional, Croly, S., additional, Coutifaris, C., additional, Cimadomo, D., additional, Dusi, L., additional, Colamaria, S., additional, Baroni, E., additional, Giuliani, M., additional, Sapienza, F., additional, Buffo, L., additional, Zivi, E., additional, Aizenman, E., additional, Barash, D., additional, Gibson, D., additional, Shufaro, Y., additional, Perez, M., additional, Aguilar, J., additional, Taboas, E., additional, Ojeda, M., additional, Suarez, L., additional, Munoz, E., additional, Casciani, V., additional, Minasi, M. G., additional, Scarselli, F., additional, Terribile, M., additional, Zavaglia, D., additional, Colasante, A., additional, Franco, G., additional, Greco, E., additional, Hickman, C., additional, Cook, C., additional, Gwinnett, D., additional, Trew, G., additional, Carby, A., additional, Lavery, S., additional, Asgari, L., additional, Paouneskou, D., additional, Jayaprakasan, K., additional, Maalouf, W., additional, Campbell, B. K., additional, Rega, E., additional, Alteri, A., additional, Cotarelo, R. P., additional, Rubino, P., additional, Colicchia, A., additional, Giannini, P., additional, Devjak, R., additional, Papler, T. B., additional, Tacer, K. F., additional, Verdenik, I., additional, Iussig, B., additional, Gala, A., additional, Ferrieres, A., additional, Vincens, C., additional, Bringer-Deutsch, S., additional, Brunet, C., additional, Conaghan, J., additional, Tan, L., additional, Gvakharia, M., additional, Ivani, K., additional, Chen, A., additional, Pera, R. R., additional, Bowman, N., additional, Montgomery, S., additional, Best, L., additional, Duffy, S., additional, Hirata, R., additional, Aoi, Y., additional, Habara, T., additional, Hayashi, N., additional, Dinopoulou, V., additional, Partsinevelos, G. A., additional, Bletsa, R., additional, Mavrogianni, D., additional, Anagnostou, E., additional, Stefanidis, K., additional, Drakakis, P., additional, Loutradis, D., additional, Hernandez, J., additional, Leon, C. L., additional, Puopolo, M., additional, Palumbo, A., additional, Atig, F., additional, Kerkeni, A., additional, D'Ommar, G., additional, Herrera, A. K., additional, Lozano, L., additional, Majerfeld, M., additional, Ye, Z., additional, Zaninovic, N., additional, Clarke, R., additional, Bodine, R., additional, Nagorny, V., additional, Zabala, A., additional, Pessino, T., additional, Outeda, S., additional, Blanco, L., additional, Leocata, F., additional, Asch, R., additional, Rajikin, M. H., additional, Nuraliza, A. S., additional, Machac, S., additional, Hubinka, V., additional, Larman, M., additional, Koudelka, M., additional, Budak, T. P., additional, Membrado, O. O., additional, Martinez, E. S., additional, Wilson, P., additional, McClure, A., additional, Nargund, G., additional, Raso, D., additional, Insua, M. F., additional, Lotti, B., additional, Giordana, S., additional, Baldi, C., additional, Barattini, J., additional, Cogorno, M., additional, Peri, N. F., additional, Neuspiller, F., additional, Resta, S., additional, Filannino, A., additional, Maggi, E., additional, Cafueri, G., additional, Ferraretti, A. P., additional, Magli, M. C., additional, Gianaroli, L., additional, Sioga, A., additional, Oikonomou, Z., additional, Chatzimeletiou, K., additional, Oikonomou, L., additional, Kolibianakis, E., additional, Tarlatzis, B. C., additional, Sarkar, M. R., additional, Ray, D., additional, Bhattacharya, J., additional, Alises, J. M., additional, Gumbao, D., additional, Hickman, C. F. L., additional, Fiorentino, I., additional, Gualtieri, R., additional, Barbato, V., additional, Braun, S., additional, Mollo, V., additional, Netti, P., additional, Talevi, R., additional, Bayram, A., additional, Findikli, N., additional, Serdarogullari, M., additional, Sahin, O., additional, Ulug, U., additional, Tosun, S. B., additional, Bahceci, M., additional, Leon, A. S., additional, Cardoso, M. C. A., additional, Aguiar, A. P. S., additional, Sartorio, C., additional, Evangelista, A., additional, Gallo-Sa, P., additional, Erthal-Martins, M. C., additional, Mantikou, E., additional, Jonker, M. J., additional, de Jong, M., additional, Wong, K. M., additional, van Montfoort, A. P. A., additional, Breit, T. M., additional, Repping, S., additional, Mastenbroek, S., additional, Power, E., additional, Jordan, K., additional, Aksoy, T., additional, Gultomruk, M., additional, Aktan, A., additional, Goktas, C., additional, Petracco, R., additional, Okada, L., additional, Azambuja, R., additional, Badalotti, F., additional, Michelon, J., additional, Reig, V., additional, Kvitko, D., additional, Tagliani-Ribeiro, A., additional, Badalotti, M., additional, Petracco, A., additional, Aydin, B., additional, Cepni, I., additional, Rodriguez-Arnedo, D., additional, Ten, J., additional, Guerrero, J., additional, Ochando, I., additional, and Bernabeu, R., additional

Published
2013
Full Text
View/download PDF

21. Posters * Fertility Preservation

Author

Talevi, R., primary, Barbato, V., additional, Mollo, V., additional, De Stefano, C., additional, Finelli, F., additional, Ferraro, R., additional, Gualtieri, R., additional, Zhou, P., additional, Liu, A. H., additional, Cao, Y. X., additional, Roman, H., additional, Pura, I., additional, Tarta, O., additional, Bourdel, N., additional, Marpeau, L., additional, Sabourin, J. C., additional, Portmann, M., additional, Nagy, Z. P., additional, Behr, B., additional, Alvaro Mercadal, B., additional, Demeestere, I., additional, Imbert, R., additional, Englert, Y., additional, Delbaere, A., additional, Lueke, S., additional, Buendgen, N., additional, Koester, F., additional, Diedrich, K., additional, Griesinger, G., additional, Kim, A., additional, Han, J. E., additional, Eunmi, C., additional, Kim, Y. S., additional, Cho, J. H., additional, Yoon, T. K., additional, Piomboni, P., additional, Stendardi, A., additional, Palumberi, D., additional, Morgante, G., additional, De Leo, V., additional, Serafini, F., additional, Focarelli, R., additional, Tatone, C., additional, Di Emidio, G., additional, Carbone, M. C., additional, Vento, M., additional, Ciriminna, R., additional, Artini, P. G., additional, Kyono, K., additional, Ishikawa, T., additional, Usui, K., additional, Hatori, M., additional, Yasmin, L., additional, Sato, E., additional, Iwasaka, M., additional, Fujii, K., additional, Owada, N., additional, Sankai, T., additional, McLaughlin, M., additional, Fineron, P., additional, Anderson, R. A., additional, Wallace, W. H. B., additional, Telfer, E. E., additional, Labied, S., additional, Beliard, A., additional, Munaut, C., additional, Foidart, J. M., additional, Turkcuoglu, I., additional, Oktay, K., additional, Rodriguez-Wallberg, K., additional, Kuwayama, M., additional, Takayama, Y., additional, Mori, C., additional, Kagawa, N., additional, Akakubo, N., additional, Takehara, Y., additional, Kato, K., additional, Leibo, S. P., additional, Kato, O., additional, Yoon, H., additional, Shin, Y., additional, cha, J., additional, Kim, H., additional, Lee, W., additional, Yoon, S., additional, Lim, J., additional, Larman, M. G., additional, Gardner, D. K., additional, Zander-Fox, D., additional, Lane, M., additional, Hamilton, H., additional, Lee, S., additional, Ozkavukcu, S., additional, Heytens, E., additional, Alappat, R. M., additional, Sole, M., additional, Boada, M., additional, Biadiu, M., additional, Santalo, J., additional, Coroleu, B., additional, Barri, P. N., additional, Veiga, A., additional, Rossi, L., additional, Bartoletti, R., additional, Mengarelli, M., additional, Boccia Artieri, G., additional, Gemini, L., additional, Mazzoli, L., additional, Giannini, L., additional, Scaravelli, G., additional, Silber, S. J., additional, Yamanguchi, S., additional, Nagumo, Y., additional, Takai, Y., additional, Ishihara, S., additional, Soleimani, R., additional, Rottiers, I., additional, Gojayev, A., additional, Cuvelier, A. C., additional, De Sutter, P., additional, Salama, M., additional, Winkler, K., additional, Murach, K. F., additional, Hofer, S., additional, Wildt, L., additional, Friess, S. C., additional, Okumura, N., additional, Kuji, N., additional, Kishimi, A., additional, Nishio, H., additional, Mochimaru, Y., additional, Minegishi, K., additional, Miyakoshi, K., additional, Fujii, T., additional, Tanaka, M., additional, Aoki, D., additional, Yoshimura, Y., additional, Hasegawa, K., additional, Juanzi, S., additional, Zhao, W., additional, Zhang, S., additional, Xue, X., additional, Silber, S., additional, Zhang, J., additional, Meirow, D., additional, Gosden, R., additional, Westphal, J. R., additional, Gerritse, R., additional, Beerendonk, C. C. M., additional, Braat, D. D. M., additional, Peek, R., additional, Coticchio, G., additional, Dal Canto, M., additional, Brambillasca, F., additional, Mignini Renzini, M., additional, Merola, M., additional, Lain, M., additional, Fadini, R., additional, Nottola, S. A., additional, Albani, E., additional, Lorenzo, C., additional, Carlini, T., additional, Maione, M., additional, Borini, A., additional, Macchiarelli, G., additional, Levi-Setti, P. E., additional, Rienzi, L., additional, Romano, S., additional, Capalbo, A., additional, Iussig, B., additional, Albricci, L., additional, Colamaria, S., additional, Baroni, E., additional, Sapienza, F., additional, Giuliani, M., additional, Anniballo, R., additional, Ubaldi, F. M., additional, Beyer, D. A., additional, Schultze-Mosgau, A., additional, Amari, F., additional, Al-Hasani, S., additional, Resta, S., additional, Magli, M. C., additional, Ruberti, A., additional, Lappi, M., additional, Ferraretti, A. P., additional, Gianaroli, L., additional, Prisant, N., additional, Belloc, S., additional, Cohen-Bacrie, M., additional, Hazout, A., additional, Olivennes, F., additional, Aubriot, F. X., additional, Alvarez, S., additional, De Mouzon, J., additional, Thieulin, C., additional, Cohen-Bacrie, P., additional, Wozniak, S., additional, Szkodziak, P., additional, Wozniakowska, E., additional, Paszkowski, M., additional, Paszkowski, T., additional, Diaz, D., additional, Dragnic, S., additional, Hayward, B., additional, Bennett, R., additional, Al-Sabbagh, A., additional, Novella-Maestre, E., additional, Teruel, J., additional, Carmona, L., additional, Rosello, E., additional, Pellicer, A., additional, Sanchez-Serrano, M., additional, Lee, J. R., additional, Lee, J. Y., additional, Kim, C. H., additional, Lee, Y., additional, Jee, B. C., additional, Suh, C. S., additional, Kim, S. H., additional, Moon, S. Y., additional, Mirabet, V., additional, Crespo, J., additional, Schiewe, M., additional, Nugent, N., additional, Zozula, S., additional, Anderson, R., additional, Zulategui, J. F., additional, Meseguer, M., additional, Remohi, J., additional, Castello, D., additional, Romero, J. L. L., additional, De los Santos, M. J., additional, Cobo, A. C., additional, von Wolff, M., additional, Jauckus, J., additional, Kupka, M., additional, Strowitzki, T., additional, Lawrenz, B., additional, Raanani, H., additional, Kaufman, B., additional, Maman, E., additional, Mendel, M. M., additional, Dor, J., additional, Buendgen, N. K., additional, Combelles, C., additional, Wang, H. Y., additional, Racowsky, C., additional, Kuleshova, L., additional, Tucker, M., additional, Graham, J., additional, Richter, K., additional, Carter, J., additional, and Levy, M., additional

Published
2010
Full Text
View/download PDF

30. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase.

Author

López B, Querejeta R, González A, Larman M, Díez J, López, Begoña, Querejeta, Ramón, González, Arantxa, Larman, Mariano, and Díez, Javier

Abstract

We investigated whether the quality of myocardial collagen associates with elevated left-sided filling pressures in 38 hypertensive patients with stage C chronic heart failure. Filling pressures were assessed invasively measuring pulmonary capillary wedge pressure. Left ventricular chamber stiffness constant was calculated from the deceleration time of the early mitral filling wave. The fraction of myocardial volume occupied by total collagen tissue and collagen type I fibers was assessed histomorphologically. The degree of collagen cross-linking (CCL), which determines the formation of insoluble stiff collagen, was assessed by colorimetric and enzymatic procedures. The expression of lysyl oxidase (LOX), which regulates CCL, was assessed by Western blot. Compared with patients with normal pulmonary capillary wedge pressure (≤12 mm Hg; n=16), patients with elevated pulmonary capillary wedge pressure (>12 mm Hg; n=22) exhibited increases of left ventricular chamber stiffness constant, fraction of myocardial volume occupied by total collagen tissue, fraction of myocardial volume occupied by collagen type I fibers, CCL, insoluble stiff collagen, and LOX. Pulmonary capillary wedge pressure was correlated with left ventricular chamber stiffness constant (r=0.639; P<0.001), insoluble stiff collagen (r=0.474; P<0.005), CCL (r=0.625; P<0.001), and LOX (r=0.410; P<0.05) in all of the patients but not with fraction of myocardial volume occupied by total collagen tissue or fraction of myocardial volume occupied by collagen type I fibers. In addition, CCL was correlated with insoluble stiff collagen (r=0.612; P<0.005), LOX (r=0.538; P<0.01), left ventricular chamber stiffness constant (r=0.535; P<0.005), peak filling rate (r=-0.343; P<0.05), ejection fraction (r=-0.430; P<0.01), and amino-terminal propeptide of brain natriuretic peptide (r=0.421; P<0.05) in all of the patients. These associations were independent of confounding factors. These findings indicate that, in hypertensive patients with stage C heart failure, it is only the quality of collagen (ie, degree of cross-linking) that associates with elevated filling pressures. It is suggested that LOX-mediated excessive CCL facilitates the increase in left ventricular stiffness with the resulting elevation of filling pressures in these patients. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

33. Maintenance of the meiotic spindle during vitrification in human and mouse oocytes.

Author

Larman, M. G., Minasi, M. G., Rienzi, L., and Gardner, D. K.

Subjects
*OVUM, *SPINDLE apparatus, *POLARIZATION microscopy, *TEMPERATURE, *FERTILIZATION (Biology)
Abstract

Vitrification appears to be a viable method for the cryopreservation of human metaphase II (MII) oocytes, but concerns regarding the concentration of cryoprotectants used during vitrification have been raised. In an attempt to circumvent this potential problem, the majority of protocols are carried out at room temperature. Exposing oocytes to temperatures below 37°C, however, leads to rapid microtubule depolymerization. Polarized light microscopy was used to measure meiotic spindle retardance following exposure to cryoprotectants and vitrification in human and mouse oocytes. To quantify the extent of depolymerization, spindle retardance was determined before and after each treatment. Exposure to vitrification and warming solutions at room temperature (21-22°C) caused the spindle of mouse MII oocytes to depolymerize. In contrast, no measurable changes in the meiotic spindle were detected by maintaining the temperature at 37°C during the exposure regimen. By carrying out the entire vitrification and warming procedure at 37°C, the spindle was also unaffected. Comparable results were obtained with vitrification of human MII oocytes at 37°C. Analysis of sibling human oocytes demonstrated that slow freezing, in contrast to vitrification, was unable to preserve the meiotic spindle. Using a vitrification protocol employing 37°C impacts negligibly on the meiotic spindle. Thus, fertilization can proceed without having to await spindle reformation. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

43. Spanish cardiac catheterization and coronary intervention registry. 33rd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2023).

Author

Bastante T, Arzamendi D, Martín-Moreiras J, Cid Álvarez AB, Carballo Garrido J, Andraka L, Gómez Jaume A, Merino Otermin Á, Artáiz Urdaci M, Ruiz Salmerón R, Pérez de Prado A, Cruz González I, Calviño Santos R, Bayón J, Trillo R, Antonio Baz J, Berenguer A, Casanova Sandoval JM, Álvarez Antón S, Sabaté M, Ruiz Nodar JM, Valero Picher E, Amat Santos IJ, Ruiz Arroyo JR, Pinar Bermúdez E, Íñigo-García LA, Arzamendi D, Jerez Valero M, Cerrato García P, Bosch Peligero E, Vaquerizo Montilla B, Subinas Elorriaga A, Sánchez Pérez I, Jiménez Mazuecos FJ, Tejada Ponce D, Santos Martínez S, Moreu J, Elízaga J, Cascón Pérez JD, García E, Mainar V, Ávila González MDM, Vergara R, Macaya C, Rasines Rodríguez A, Fernández-Ortiz A, Ojeda Pineda S, Bethencourt González A, Palazuelos J, López Palop R, Alegría Barrero E, Camacho Freire SJ, Portero Pérez MP, Peña Perez G, Vázquez Álvarez ME, Roura G, Agudelo V, Freixa X, Carrillo X, Mohandes M, Muñoz Camacho JF, Millán R, García Del Blanco B, Sarnago F, Torres Bosco A, Sáez R, Avanzas P, Pérez Vizcayno MJ, Caballero Borrego J, Blanco Mata R, Merchán Herrera A, Luengo Mondéjar P, Lozano Í, Portales Fernández J, Bosa Ojeda F, Martín Lorenzo P, Novo García E, Fernández Guerrero JC, González Caballero E, Rivero F, Pomar F, Ruiz Quevedo V, Morales Ponce FJ, Ruiz García J, Romero Vazquiánez M, Tellería M, Baello Monge P, Botas Rodríguez J, Franco Peláez JA, Unzue L, Gómez Menchero AE, Sánchez Recalde Á, Jurado Román A, Sainz Laso F, Fuertes Ferre G, Pimienta González R, Oteo Domínguez JF, Gutiérrez A, Bullones Ramírez JA, Sánchez-Aquino González R, Frutos Garcia A, Fajardo Molina R, Núñez Pernas D, Alonso Briales JH, Sánchez Gila J, Sánchez Burguillos FJ, Guisado Rasco A, Vizcaino Arellano M, Díez Gil JL, de la Borbolla Fernández RG, Ramírez A, and Larman M

Subjects
Spain, Humans, Registries, Cardiac Catheterization methods, Cardiac Catheterization statistics & numerical data, Societies, Medical, Percutaneous Coronary Intervention methods, Percutaneous Coronary Intervention statistics & numerical data, Cardiology
Abstract

Introduction and Objectives: This article presents the 2023 activity report of the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC)., Methods: All interventional cardiology laboratories in Spain were invited to participate in an online survey. Data analysis was carried out by an external company and subsequently reviewed and presented by the members of the ACI-SEC board., Results: A total of 119 hospitals participated. The number of diagnostic studies decreased by 1.8%, while the number of percutaneous coronary interventions (PCI) showed a slight increase. There was a reduction in the number of stents used and an increase in the use of drug-coated balloons. The use of intracoronary diagnostic techniques remained stable. For the first time, data on PCI guided by intracoronary imaging was reported, showing a 10% usage rate in Spain. Techniques for plaque modification continued to grow. Primary PCI increased, becoming the predominant treatment for myocardial infarction (97%). Noncoronary structural procedures continued their upward trend. Notably, the number of left atrial appendage closures, patent foramen ovale closures, and tricuspid valve interventions grew in 2023. There was also a significant increase in interventions for acute pulmonary embolism., Conclusions: The 2023 Spanish cardiac catheterization and coronary intervention registry indicates a stabilization in coronary interventions, together with an increase in complexity. There was consistent growth in procedures for both valvular and nonvalvular structural heart diseases., (Copyright © 2024 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)

Published
2024
Full Text
View/download PDF

44. Towards Automation in IVF: Pre-Clinical Validation of a Deep Learning-Based Embryo Grading System during PGT-A Cycles.

Author

Cimadomo D, Chiappetta V, Innocenti F, Saturno G, Taggi M, Marconetto A, Casciani V, Albricci L, Maggiulli R, Coticchio G, Ahlström A, Berntsen J, Larman M, Borini A, Vaiarelli A, Ubaldi FM, and Rienzi L

Abstract

Preimplantation genetic testing for aneuploidies (PGT-A) is arguably the most effective embryo selection strategy. Nevertheless, it requires greater workload, costs, and expertise. Therefore, a quest towards user-friendly, non-invasive strategies is ongoing. Although insufficient to replace PGT-A, embryo morphological evaluation is significantly associated with embryonic competence, but scarcely reproducible. Recently, artificial intelligence-powered analyses have been proposed to objectify and automate image evaluations. iDAScore v1.0 is a deep-learning model based on a 3D convolutional neural network trained on time-lapse videos from implanted and non-implanted blastocysts. It is a decision support system for ranking blastocysts without manual input. This retrospective, pre-clinical, external validation included 3604 blastocysts and 808 euploid transfers from 1232 cycles. All blastocysts were retrospectively assessed through the iDAScore v1.0; therefore, it did not influence embryologists' decision-making process. iDAScore v1.0 was significantly associated with embryo morphology and competence, although AUCs for euploidy and live-birth prediction were 0.60 and 0.66, respectively, which is rather comparable to embryologists' performance. Nevertheless, iDAScore v1.0 is objective and reproducible, while embryologists' evaluations are not. In a retrospective simulation, iDAScore v1.0 would have ranked euploid blastocysts as top quality in 63% of cases with one or more euploid and aneuploid blastocysts, and it would have questioned embryologists' ranking in 48% of cases with two or more euploid blastocysts and one or more live birth. Therefore, iDAScore v1.0 may objectify embryologists' evaluations, but randomized controlled trials are required to assess its clinical value.

Published
2023
Full Text
View/download PDF

45. Transradial Crossover Balloon Occlusion Technique for Primary Access Hemostasis During Transcatheter Aortic Valve Replacement: Initial Experience With the Oceanus 140 cm and 200 cm Balloon Catheters.

Author

Junquera L, Vilalta V, Trillo R, Sabaté M, Latib A, Nombela-Franco L, Moris C, Garcia Del Blanco B, Larman M, Hernandez JM, Iñiguez A, Amat-Santos I, Fernandez-Nofrerias E, Regueiro A, Colombo A, Tzanis G, Jiménez-Quevedo P, Pérez-Serranos I, Duran-Priu M, Duocastella L, Paradis JM, and Rodés Cabau J

Subjects
Aged, Aged, 80 and over, Aortic Valve diagnostic imaging, Aortic Valve surgery, Female, Femoral Artery surgery, Hemostasis, Humans, Male, Treatment Outcome, Aortic Valve Stenosis diagnosis, Aortic Valve Stenosis surgery, Balloon Occlusion, Transcatheter Aortic Valve Replacement adverse effects
Abstract

Objectives: The crossover balloon occlusion technique (CBOT) facilitates primary access hemostasis in patients undergoing transfemoral transcatheter aortic valve replacement (TAVR). The CBOT is usually performed through the contralateral femoral artery. The aim of this study was to evaluate, in patients undergoing TAVR, the safety and feasibility of transradial CBOT using the new Oceanus balloon dilatation catheter (iVascular)., Methods: This multicenter study included 104 patients (mean age, 81 ± 7 years; 43% women) undergoing transfemoral TAVR. A modified CBOT through the radial artery was performed in all patients with the Oceanus balloon catheter. Data regarding transradial CBOT, balloon performance, vascular complications, and 30-day clinical events were recorded., Results: Up to 21% of patients had a height >170 cm and 17% presented with severe aortic/iliofemoral tortuosity. The transradial CBOT (left radial 74%, right radial 26%) was performed using either the 140 cm Oceanus (37.5%) or the 200 cm Oceanus (62.5%) balloon catheter. The balloon reached the femoral artery in all patients, and balloon inflation achieved an appropriate vessel closure in 98%. There were no complications related to the balloon catheter, and only 1 patient (1.0%) suffered a minor vascular complication related to the secondary radial access. The 30-day rates of primary access major vascular complications and death were 3.8% and 1.9%, respectively., Conclusion: In patients undergoing transfemoral TAVR, transradial CBOT with the Oceanus balloon dilatation catheter was feasible and safe. A balloon length up to 200 cm allowed the use of this technique (from right or left radial access) in all patients regardless of patient height or the presence of a challenging vascular anatomy.

Published
2020
Full Text
View/download PDF

46. Transcatheter Aortic Valve Replacement on an Aortic Mechanical Valve.

Author

Arzamendi D, Ruiz V, Ramallal R, Alcasena MS, Beunza MT, and Larman M

Subjects
Aged, Aortic Valve diagnostic imaging, Aortic Valve Insufficiency diagnostic imaging, Aortic Valve Insufficiency etiology, Female, Heart Valve Prosthesis Implantation adverse effects, Humans, Prosthesis Failure, Reoperation, Treatment Outcome, Aortic Valve surgery, Aortic Valve Insufficiency surgery, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation instrumentation, Rheumatic Heart Disease surgery, Transcatheter Aortic Valve Replacement instrumentation
Published
2018
Full Text
View/download PDF

47. Angina and Ischemia at 2 Years With Bioresorbable Vascular Scaffolds and Metallic Drug-eluting Stents. ESTROFA Ischemia BVS-mDES Study.

Author

de la Torre Hernández JM, Rumoroso JR, Ojeda S, Brugaletta S, Cascón JD, Ruisánchez C, Sánchez Gila J, Roa J, Tizón H, Gutiérrez H, Larman M, García Camarero T, Pinar E, Díaz JF, Pan M, Morillas Bueno M, Oyonarte JM, Ruiz Guerrero L, Ble M, Rubio Patón R, Arnold R, Echegaray K, de la Morena G, and Sabate M

Subjects
Absorbable Implants, Aged, Angina Pectoris diagnosis, Cohort Studies, Electrocardiography methods, Everolimus pharmacology, Female, Follow-Up Studies, Humans, Male, Metals, Middle Aged, Myocardial Ischemia diagnosis, Percutaneous Coronary Intervention methods, Propensity Score, Retrospective Studies, Risk Assessment, Severity of Illness Index, Tertiary Care Centers, Time Factors, Treatment Outcome, Angina Pectoris therapy, Drug-Eluting Stents, Echocardiography, Stress methods, Myocardial Ischemia therapy, Percutaneous Coronary Intervention instrumentation, Tissue Scaffolds
Abstract

Introduction and Objectives: Bioresorbable vascular scaffolds (BVS) have the potential to restore vasomotion but the clinical implications are unknown. We sought to evaluate angina and ischemia in the long-term in patients treated with BVS and metallic drug-eluting stents (mDES)., Methods: Multicenter study including patients with 24 ± 6 months of uneventful follow-up, in which stress echocardiography was performed and functional status was assessed by the Seattle Angina Questionnaire (SAQ). The primary endpoint was a positive result in stress echocardiography., Results: The study included 102 patients treated with BVS and 106 with mDES. There were no differences in the patients' baseline characteristics. Recurrent angina was found in 18 patients (17.6%) in the BVS group vs 25 (23.5%) in the mDES group (P = .37), but SAQ results were significantly better in the BVS group (angina frequency 96.0 ± 8.0 vs 89.2 ± 29.7; P = .02). Stress echocardiography was positive in 11/92 (11.9%) of BVS patients vs 9/96 (9.4%) of mDES patients in the (P = .71) and angina was induced in 2/102 (1.9%) vs 7/106 (6.6%) (P = .18), respectively, but exercise performance was better in the BVS group even in those with positive tests (exercise duration 9.0 ± 2.0minutes vs 7.7 ± 1.8minutes; P = .02). A propensity score matching analysis yielded similar results., Conclusions: The primary endpoint was similar in both groups. In addition, recurrent angina was similar in patients with BVS and mDES. The better functional status, assessed by means of SAQ and exercise performance, detected in patients receiving BVS should be confirmed in further studies., (Copyright © 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)

Published
2018
Full Text
View/download PDF

48. Intracardiac shunts following transcatheter aortic valve implantation: a multicentre study.

Author

Amat-Santos IJ, Rojas P, Stella PR, Nombela-Franco L, Lezáun-Burgui R, Muñoz-García AJ, Serra V, Gutierrez-Ibanes E, Larman M, Rodriguez-Olivares R, Kooistra NHM, Gutiérrez H, and San Román JA

Subjects
Aged, Aged, 80 and over, Aortic Valve Stenosis mortality, Aortic Valve Stenosis surgery, Female, Follow-Up Studies, Heart Failure diagnosis, Heart Failure etiology, Heart Failure mortality, Hospital Mortality, Humans, Incidence, Male, Mitral Valve diagnostic imaging, Outcome and Process Assessment, Health Care, Prognosis, Registries statistics & numerical data, Risk Factors, Spain epidemiology, Tomography, X-Ray Computed methods, Transcatheter Aortic Valve Replacement methods, Ventricular Septum diagnostic imaging, Wound Closure Techniques statistics & numerical data, Intraoperative Complications epidemiology, Intraoperative Complications etiology, Intraoperative Complications therapy, Mitral Valve injuries, Postoperative Complications classification, Postoperative Complications epidemiology, Postoperative Complications etiology, Postoperative Complications therapy, Prosthesis-Related Infections epidemiology, Prosthesis-Related Infections etiology, Prosthesis-Related Infections therapy, Transcatheter Aortic Valve Replacement adverse effects, Ventricular Septum injuries
Abstract

Aims: The aim of this study was to describe the incidence, mechanisms, management and outcomes of intracardiac shunts (ICS) following TAVI., Methods and Results: This was a multicentre registry across 10 centres aimed at gathering all cases of ICS (1.1%) including infection-related (IRICS, 0.3%) or aseptic (AICS, 0.8%) shunts. Patients presented porcelain aorta (24% vs. 6.8%, p=0.024) and had been treated with predilation (88% vs. 68.5%, p=0.037) or post-dilation (59.1% vs. 19.3%, p<0.001) more often. Median time from intervention to diagnosis of ICS was 10 days (IQR: 2-108), being longer for IRICS (171 [63-249] vs. 3 [1-12] days, p=0.002). Interventricular septum (55.6%) and anterior mitral leaflet (57.2%) were the most common locations for AICS and IRICS, respectively. Most patients (76%) developed heart failure but 64% were medically managed. Seven patients (38.9%) underwent percutaneous closure of AICS. The in-hospital mortality rate was 44% (IRICS 100%, AICS 27.8%) compared to global TAVI recipients (8.1%, p<0.001). At one-year follow-up, 76% of the patients had died. ICS, logistic EuroSCORE, and moderate-severe residual aortic regurgitation were independent predictors of death., Conclusions: Post-TAVI ICS are an uncommon complication independently associated with high early mortality. Currently, most therapeutic alternatives yield poor results but percutaneous closure of AICS was feasible and is a promising alternative.

Published
2018
Full Text
View/download PDF

49. Prosthetic Mitral Surgical Valve in Transcatheter Aortic Valve Replacement Recipients: A Multicenter Analysis.

Author

Amat-Santos IJ, Cortés C, Nombela Franco L, Muñoz-García AJ, Suárez De Lezo J, Gutiérrez-Ibañes E, Serra V, Larman M, Moreno R, De La Torre Hernandez JM, Puri R, Jimenez-Quevedo P, Hernández García JM, Alonso-Briales JH, García B, Lee DH, Rojas P, Sevilla T, Goncalves R, Vera S, Gómez I, Rodés-Cabau J, and San Román JA

Subjects
Aged, Aged, 80 and over, Aortic Valve diagnostic imaging, Aortic Valve physiopathology, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis mortality, Aortic Valve Stenosis physiopathology, Female, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation mortality, Humans, Male, Mitral Valve diagnostic imaging, Mitral Valve physiopathology, Postoperative Complications etiology, Prosthesis Design, Registries, Retrospective Studies, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Aortic Valve surgery, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation instrumentation, Mitral Valve surgery, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement mortality
Abstract

Objectives: The aim of this study was to determine the prognosis and specific complications of patients with prosthetic mitral valves (PMVs) undergoing transcatheter aortic valve replacement (TAVR)., Background: TAVR is performed relatively often in patients with PMVs, but specific risks are not well described., Methods: A multicenter analysis was conducted, including patients with severe symptomatic aortic stenosis who underwent TAVR at 10 centers. Patients' clinical characteristics and outcomes were evaluated according to the presence of a PMV., Results: The mean age of the study population (n = 2,414) was 81 ± 8 years, and 48.8% were men. A total of 91 patients (3.77%) had PMVs. They were more commonly women, younger, and had higher surgical risk. PMVs were implanted a median of 14 years before TAVR, and most patients had mechanical prostheses (73.6%). Eighty-six patients (94.5%) were on long-term vitamin K inhibitor therapy, and bridging antithrombotic therapy was administered in 59 (64.8%). TAVR device embolization occurred in 6.7% (vs. 3.3% in the non-PMV group; p = 0.127), in all instances when distance between the PMV and the aortic annulus was <7 mm. Mortality rates did not show a difference, but the rate of bleeding was higher in patients with PMV (24.2% vs. 16.1%; p = 0.041), even in those treated via the transfemoral approach (22.2% vs. 13.9%; p = 0.048). Indeed, bleeding complications, prior atrial fibrillation, chronic obstructive pulmonary disease, surgical risk, and New York Heart Association functional class were independent predictors of mortality., Conclusions: TAVR presents similar mortality irrespective of the presence of a PMV. However, patients with PMVs had higher bleeding risk that was independently associated with higher mortality. Risk for valve embolization was relatively high, but it occurred only in patients with PMV-to-aortic annulus distances <7 mm., (Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

Published
2017
Full Text
View/download PDF

50. Puncture Versus Surgical Cutdown Complications of Transfemoral Aortic Valve Implantation (from the Spanish TAVI Registry).

Author

Hernández-Enriquez M, Andrea R, Brugaletta S, Jiménez-Quevedo P, Hernández-García JM, Trillo R, Larman M, Fernández-Avilés F, Vázquez-González N, Iñiguez A, Zueco J, Ruiz-Salmerón R, Del Valle R, Molina E, García Del Blanco B, Berenguer A, Valdés M, Moreno R, Urbano-Carrillo C, Hernández-Antolín R, Gimeno F, Cequier Á, Cruz I, López-Mínguez JR, Aramendi JI, Sánchez Á, Goicolea J, Albarrán A, Díaz JF, Navarro F, Moreu J, Morist A, Fernández-Nofrerías E, Fernández-Vázquez F, Ten F, Mainar V, Mari B, Saenz A, Alfonso F, Diarte JA, Sancho M, Lezáun R, Arzamendi D, and Sabaté M

Subjects
Aged, Aged, 80 and over, Contrast Media, Female, Fluoroscopy, Humans, Kaplan-Meier Estimate, Length of Stay, Male, Operative Time, Postoperative Complications epidemiology, Proportional Hazards Models, Spain, Aortic Valve Stenosis surgery, Dissection methods, Femoral Artery, Myocardial Infarction epidemiology, Postoperative Hemorrhage epidemiology, Punctures methods, Registries, Transcatheter Aortic Valve Replacement methods
Abstract

Vascular complications in transcatheter aortic valve implantation using transfemoral approach are related to higher mortality. Complete percutaneous approach is currently the preferred technique for vascular access. However, some centers still perform surgical cutdown. Our purpose was to determine complications related to vascular access technique in the population of the Spanish TAVI National Registry. From January 2010 to July 2015, 3,046 patients were included in this Registry. Of them, 2,465 underwent transfemoral approach and were treated with either surgical cutdown and closure (cutdown group, n = 632) or percutaneous approach (puncture group, n = 1,833). Valve Academic Research Consortium-2 definitions were used to assess vascular and bleeding complications. Propensity matching resulted in 615 matched pairs. Overall, 30-day vascular complications were significantly higher in the puncture group (109 [18%] vs 42 [6.9%]; relative risk [RR] 2.60; 95% confidence interval [CI] 1.85 to 3.64, p <0.001) due mostly by minor vascular events (89 [15%] vs 25 [4.1%], RR 3.56, 95% CI 2.32 to 5.47, p <0.001). Bleeding rates were lower in the puncture group (18 [3%] vs 40 [6.6%], RR 0.45, 95% CI 0.26 to 0.78, p = 0.003) mainly driven by major bleeding (9 [1.5%] vs 21 [3.4%], RR 0.43, 95% CI 0.20 to 0.93, p = 0.03). At a mean follow-up of 323 days, complication rates remained significantly different between groups (minor vascular complications 90 [15%] vs 31 [5.1%], hazard ratio 2.99, 95% CI 1.99 to 4.50, p <0.001 and major bleeding 10 [1.6%] vs 21 [3.4%], hazard ratio 0.47, 95% CI 0.22 to 1.0, p = 0.04, puncture versus cutdown group, respectively). In conclusion, percutaneous approach yielded higher rates of minor vascular complications but lower rates of major bleeding compared with the surgical cutdown, both at 30-day and at mid-term follow-up in our population., (Copyright © 2016 Elsevier Inc. All rights reserved.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results